This company listing is no longer active
DSM-Firmenich Past Earnings Performance
Past criteria checks 1/6
DSM-Firmenich's earnings have been declining at an average annual rate of -20.7%, while the Chemicals industry saw earnings growing at 10.1% annually. Revenues have been declining at an average rate of 0.8% per year. DSM-Firmenich's return on equity is 4.4%, and it has net margins of 5.4%.
Key information
-20.7%
Earnings growth rate
-20.2%
EPS growth rate
| Chemicals Industry Growth | 1.6% |
| Revenue growth rate | -0.8% |
| Return on equity | 4.4% |
| Net Margin | 5.4% |
| Next Earnings Update | 02 Aug 2023 |
Recent past performance updates
Recent updates
Analyst Forecasts For Koninklijke DSM N.V. (AMS:DSM) Are Surging Higher
May 04
Koninklijke DSM (AMS:DSM) Is Reinvesting At Lower Rates Of Return
Mar 27Is Koninklijke DSM (AMS:DSM) A Risky Investment?
Mar 09Here's Why We Think Koninklijke DSM (AMS:DSM) Is Well Worth Watching
Dec 06Is Koninklijke DSM (AMS:DSM) Using Too Much Debt?
Nov 18Estimating The Fair Value Of Koninklijke DSM N.V. (AMS:DSM)
Oct 31Why Koninklijke DSM N.V. (AMS:DSM) Could Be Worth Watching
Sep 19Is Now The Time To Put Koninklijke DSM (AMS:DSM) On Your Watchlist?
Aug 23Is Koninklijke DSM (AMS:DSM) Using Too Much Debt?
Aug 08Calculating The Intrinsic Value Of Koninklijke DSM N.V. (AMS:DSM)
Jul 23Koninklijke DSM (AMS:DSM) Is Increasing Its Dividend To €1.70
Apr 30Koninklijke DSM (AMS:DSM) Is Increasing Its Dividend To €1.70
Apr 16Koninklijke DSM's (AMS:DSM) Upcoming Dividend Will Be Larger Than Last Year's
Apr 02Koninklijke DSM's (AMS:DSM) Dividend Will Be Increased To €1.70
Mar 19Koninklijke DSM (AMS:DSM) Seems To Use Debt Rather Sparingly
Feb 19Are Koninklijke DSM N.V. (AMS:DSM) Investors Paying Above The Intrinsic Value?
Nov 23We Think Koninklijke DSM (AMS:DSM) Can Stay On Top Of Its Debt
Oct 01Does This Valuation Of Koninklijke DSM N.V. (AMS:DSM) Imply Investors Are Overpaying?
Aug 24Koninklijke DSM (AMS:DSM) Has A Pretty Healthy Balance Sheet
Jun 29Koninklijke DSM N.V.'s (AMS:DSM) Intrinsic Value Is Potentially 17% Below Its Share Price
May 24Is Koninklijke DSM (AMS:DSM) A Risky Investment?
Mar 29Should Koninklijke DSM N.V. (AMS:DSM) Be Part Of Your Dividend Portfolio?
Mar 15Are Koninklijke DSM N.V.'s (AMS:DSM) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
Mar 01Koninklijke DSM (AMS:DSM) Has Gifted Shareholders With A Fantastic 276% Total Return On Their Investment
Feb 16Need To Know: Koninklijke DSM N.V. (AMS:DSM) Insiders Have Been Selling Shares
Feb 04
Revenue & Expenses BreakdownBeta
How DSM-Firmenich makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 8,390 | 454 | 1,772 | 295 |
| 30 Sep 22 | 9,582 | 837 | 895 | 162 |
| 30 Jun 22 | 9,802 | 1,082 | 1,789 | 323 |
| 31 Mar 22 | 9,503 | 1,081 | 1,789 | 323 |
| 31 Dec 21 | 7,269 | 820 | 1,649 | 274 |
| 30 Sep 21 | 7,955 | 660 | 2,517 | 560 |
| 30 Jun 21 | 7,558 | 493 | 1,622 | 398 |
| 31 Mar 21 | 7,572 | 423 | 1,622 | 398 |
| 31 Dec 20 | 8,106 | 448 | 1,622 | 398 |
| 30 Sep 20 | 7,960 | 510 | 1,639 | 295 |
| 30 Jun 20 | 8,034 | 557 | 1,639 | 295 |
| 31 Mar 20 | 9,011 | 722 | 1,795 | 349 |
| 31 Dec 19 | 7,998 | 675 | 1,639 | 295 |
| 30 Sep 19 | 8,272 | 820 | 1,839 | 348 |
| 30 Jun 19 | 8,502 | 794 | 1,839 | 348 |
| 31 Mar 19 | 9,124 | 934 | 1,839 | 348 |
| 31 Dec 18 | 9,267 | 1,069 | 1,839 | 348 |
| 30 Sep 18 | 9,235 | 984 | 1,753 | 334 |
| 30 Jun 18 | 9,106 | 2,082 | 1,753 | 334 |
| 31 Mar 18 | 8,908 | 1,942 | 1,753 | 334 |
| 31 Dec 17 | 8,632 | 1,761 | 1,753 | 334 |
| 30 Sep 17 | 8,471 | 1,676 | 1,694 | 309 |
| 30 Jun 17 | 8,333 | 738 | 1,694 | 309 |
| 31 Mar 17 | 8,166 | 711 | 1,694 | 309 |
| 31 Dec 16 | 7,920 | 645 | 1,694 | 309 |
| 30 Sep 16 | 7,831 | 588 | 1,605 | 332 |
| 30 Jun 16 | 7,778 | 274 | 1,605 | 332 |
| 31 Mar 16 | 7,749 | 214 | 1,605 | 332 |
| 31 Dec 15 | 7,722 | 174 | 1,605 | 332 |
| 30 Sep 15 | 7,607 | 66 | 1,382 | 304 |
| 30 Jun 15 | 7,456 | 114 | 1,382 | 304 |
| 31 Mar 15 | 7,245 | 115 | 1,382 | 304 |
| 31 Dec 14 | 7,051 | 123 | 1,382 | 304 |
| 30 Sep 14 | 7,415 | 112 | 1,430 | 340 |
| 30 Jun 14 | 7,834 | 138 | 1,430 | 340 |
| 31 Mar 14 | 8,362 | 182 | 1,430 | 340 |
| 31 Dec 13 | 8,858 | 252 | 1,430 | 340 |
| 30 Sep 13 | 8,409 | 363 | 1,396 | 372 |
| 30 Jun 13 | 8,500 | 335 | 1,396 | 372 |
| 31 Mar 13 | 8,486 | 257 | 1,396 | 372 |
| 31 Dec 12 | 8,588 | 280 | 1,396 | 372 |
| 30 Sep 12 | 9,089 | 453 | 1,356 | 378 |
| 30 Jun 12 | 9,107 | 543 | 1,356 | 378 |
Quality Earnings: DSM has high quality earnings.
Growing Profit Margin: DSM's current net profit margins (5.4%) are lower than last year (11.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DSM's earnings have declined by 20.7% per year over the past 5 years.
Accelerating Growth: DSM's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: DSM had negative earnings growth (-44.6%) over the past year, making it difficult to compare to the Chemicals industry average (-19.7%).
Return on Equity
High ROE: DSM's Return on Equity (4.4%) is considered low.